Medtronic has begun the initial European market launch of its MiniMed Duo, which combines constant glucose monitoring and an insulin pump into one unit.
The company claims that MiniMed Duo is the world’s first two-in-one breakthrough that combines a glucose sensor and insulin infusion set into one on-body device, simplifying integrated insulin pump therapy and continuous glucose monitoring.
Medtronic has designed the MiniMed Duo, which recently received CE Mark approval, for use with the MiniMed Veo system. MiniMed Duo provides enhanced simplicity with greater comfort.
Medtronic claims that MiniMed Veo is the only integrated system with an automatic insulin shut-off mechanism if glucose levels fall too low, providing protection against hypoglycemia.
Medtronic Diabetes Continuous Glucose Monitoring business general manager and vice president Greg Meehan said that MiniMed Duo is the latest breakthrough designed in response to the needs of insulin pumpers who don’t want to wear two separate devices on their bodies, addressing one of the most common barriers to CGM technology.
Pending local approvals, the MiniMed Duo will be available in select European countries in the next few months. The device is not available in the US.